Infectious Diseases in the Critically Ill Patients
Abstract
Infection is common in the critically ill and often results due to the severity of the patient’s illness. Recent data suggest 51% of intensive care unit (ICU) patients are infected, and 71% receive antimicrobial therapy. Bacterial infection is the primary concern, although some fungal infections are opportunistic. Infection more than doubles the ICU mortality rate, and the costs associated with infection may be as high as 40% of total ICU expenditures. There are many contemporary antimicrobial resistance concerns that the critical care clinician must consider in managing the pharmacotherapy of infection. Methicillin resistance in Staphylococcus aureus, vancomycin resistance in Enterococci, beta-lactamase resistance in Enterobacteriaceae, multidrug resistance in Pseudomonas aeruginosa and Acinetobacter species, fluoroquinolone resistance in Escherichia coli, and fungal resistance are among the most common issues ICU clinician’s must face in managing infection. Critical illness causes changes in pharmacokinetics that influence drug and dosing considerations. Absorption, distribution, metabolism, and excretion may all be affected by the various disease states that define critical illness. Several specific diseases are discussed, including ventilator-associated pneumonia, various fungal infections, gastrointestinal infections due to Clostridium difficile, urinary tract infections, and bloodstream infections. Within each disease section, discussion includes causes and prevention strategies, microbiology, evidence-based guidelines, and important caveats.
Get full access to this article
View all access and purchase options for this article.
References
1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–2329.
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–1310.
3. Marshall JC, Charbonney E, Gonzalez PD. The immune system in critical illness. Clin Chest Med. 2008;29(4):605–616.
4. Zilberberg MD, Shorr AF, Micek ST, et al. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest. 2008;134(5):963–968.
5. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23(1):91–100.
6. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49(4):1306–1311.
7. Leclerq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect. 2009;15(3):224–231.
8. Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant. Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008;46(6):787–794.
9. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124(5): 1789–1797
10. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–665
11. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology. 2009;155(pt 6):1749–1757.
12. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–317.
13. Tacconelli E, Cataldo MA. Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents. 2008;31(2):99–106.
14. Eliopoulos GM. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect. 2009;59(suppl 1):S17–S24.
15. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis. 2009;9(4):228–236.
16. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65(6):1119–1125.
17. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009;64(suppl 1):i29–i36.
18. Paterson DL. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Infect Control. 2006;34(5 suppl 1):S20–S28.
19. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29(11):996–1011.
20. Nguyen LH, Hsu DI, Ganapathy V, et al. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome. J Antimicrob Chemother. 2008;61(3):714–720.
21. Aarts MA, Hancock JN, Heyland D, et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2008;36(1):108–117.
22. Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36(1):737–744.
23. Murray CK, Hospenthal DR. Acinetobacter infection in the ICU. Crit Care Clin. 2008;24(2):237–248.
24. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant Gram-negative bacilli in North America; Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2008;28(2):235–249.
25. Livermore DM, Hope R, Brick G, et al. Non-susceptibility trends among enterobacteriaceae from bacteraemias in the UK and Ireland, 2001–06. J Antimicrob Chemother. 2008;62(suppl 2):ii41–ii54.
26. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother. 2007;60(5):913–920.
27. Rodriguez-Baño J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006;43(11):1407–1414.
28. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–535.
29. Boucher B, Wood G, Swanson J. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22(2):255–271. vi.
30. Dasta JF, Boucher BA, Brophy GM, et al. Intravenous to oral conversion of antihypertensives: a toolkit for guideline development. Ann Pharmacother. 2010;44(9):1430–1447.
31. Tortorici M, Kochanek P, Poloyac S. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med. 2007;35(9):2196–2204.
32. van den Broek M, Groenendaal F, Egberts A, et al. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet. 2010;49(5):277–294.
33. Iida Y, Nishi S, Asada A. Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics. Ther Drug Monit. 2001;23(3):192–197.
34. Satas S, Hoem N, Melby K, et al. Influence of mild hypothermia after hypoxia-ischemia on the pharmacokinetics of gentamicin in newborn pigs. Biol Neonate. 2000;77(1):50–57.
35. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357–363.
36. Cohen S, Gerding D, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455.
37. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.
38. Singh N, Rogers P, Atwood C, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162(2 pt 1):505–511.
39. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328(7441):668.
40. Cometta A, Baumgartner J, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother. 1994;38(6):1309–1313.
41. Chastre J, Wolff M, Fagon J, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588–2598.
42. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care. 2008;12(1):204.
43. León C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37(5):1624–1633.
44. Playford E, Lipman J, Sorrell T. Management of invasive candidiasis in the intensive care unit. Drugs. 2010;70(7):823–839.
45. Hooton TM, Bradley BF, Cardenas DD. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–663.
46. Laupland KB, Bagshaw SM, Gregson DB, et al. Intensive care unit-acquired urinary tract infections in a regional critical care system. Crit Care. 2005;9(2):R60–R65.
47. Clec’h C, Schwebel C, Francais A. et al. Does catheter-associated urinary tract infection increase mortalityt in critically ill patients? Infect Control Hosp Epidemiol. 2007;28(12):1367–1373.
48. Januel JM, Harbarth S, Allard R, et al. Estimating attributable mortality due to nosocomial infections acquired in intensive care units. Infect Control Hosp Epidemiol. 2010;31(4):399–394.
49. Nicolle LE. Catheter-related urinary tract infection. Drugs Aging. 2005;22(8):627–639.
50. Centers for Disease Control and Prevention (CDC). Monitoring hospital-acquired infections to promote patient safety—United States, 1990-1999. MMWR Morb Mortal Wkly Rep. 2000;49(8):149–153.
51. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosisand management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45.
52. Garnacho-Montero J, Aldabo-Pallas T, Palomar-Martinez M, et al. Risk factors and prognosis of catheter-related bloodstream infection in the critically ill: a multicenter study. Intensive Care Med. 2008;34(12):2185–2193.
53. Karchmer AW. Bloodstream infections: the problem and the challenge. Int J Antimicob Agents. 2009;34(suppl 4):S2–S4.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: March 9, 2011
Issue published: February 2011
Keywords
PubMed: 21507873
Authors
Metrics and citations
Metrics
Journals metrics
This article was published in Journal of Pharmacy Practice.
View All Journal MetricsArticle usage*
Total views and downloads: 584
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 0
Crossref: 31
- Sociodemographic and clinical profiles of patients receiving home care and the occurrence and management of healthcare-associated infections: a cross-sectional study
- Utilizing an Opportunistic Clinical Study and Population‐Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin–Tazobactam in Critically Ill Patients
- The relationship between energy intake and infections in critical patients in intensive care unit (ICU) receiving medical nutrition therapy at Wahidin Sudirohusodo Hospital.
- Enhanced renal clearance impacts levetiracetam concentrations in patients with traumatic brain injury with and without augmented renal clearance
- Distribution and antimicrobial resistance analysis of gram-negative bacilli isolated from a tertiary hospital in Central China: a 10-year retrospective study from 2012 to 2021
- Therapeutic Drug monitoring of colistin in critically ill patients: A narrative review
- Comparison of Race‐Based and Non–Race‐Based Equations for Kidney Function Estimation in Critically Ill Thai Patients for Vancomycin Dosing
- Digital PCR applications for the diagnosis and management of infection in critical care medicine
- Prognostic Scores and Azole-Resistant Aspergillus fumigatus in Invasive Aspergillosis from an Indian Respiratory Medicine ICU (ICU Patients with IA Suspicion)
- Burn and Trauma Associated Lung Injury
- View More
Figures and tables
Figures & Media
Tables
View Options
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
I am signed in as:
View my profileSign out
I can access personal subscriptions, purchases, paired institutional access and free tools such as favourite journals, email alerts and saved searches.
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
